Sustained supplementation and monitored response
Non-advanced age-related macular degeneration (AMD) does not profoundly affect vision, but is associated with gradual but relentless visual decline and, in many cases, progression to advanced and blinding AMD (atrophic and/or neovascular). Supplementation with antioxidants that include the macular carotenoids has been shown to benefit patients with non-advanced AMD. A recent randomized, clinical trial has shown that a formulation containing all three macular carotenoids (in L:MZ:Z [mg] ratio of 10:10:2; MacuHealth with LMZ3 and MacuHealthPlus+ ) outperforms a MZ-deficient formulation in patients with non-advanced AMD, both in terms of visual improvements and in terms of observed increases in macular pigment.
1. Chew, E.Y., et al., Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol., 2013. 132: p. 142-149.
2. Akuffo, K.O., et al., Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration. Eye (Lond). 2015: p. 10.